Search

Your search keyword '"Altintas, Ayse"' showing total 413 results
Start Over Author "Altintas, Ayse"
413 results on '"Altintas, Ayse"'

1. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Author

Lal, Anoushka P., Foong, Yi Chao, Sanfilippo, Paul G., Spelman, Tim, Rath, Louise, Levitz, David, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas-Robledo, Simón, Moghadasi, Abdorreza Naser, Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, and Van der Walt, Anneke

Published
2024
Full Text
View/download PDF

2. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

Author

Li, Ying, Saul, Alice, Taylor, Bruce, Ponsonby, Anne-Louise, Simpson-Yap, Steve, Blizzard, Leigh, Broadley, Simon, Lechner-Scott, Jeannette, Karabudak, Rana, Patti, Francesco, Eichau, Sara, Onofrj, Marco, Ozakbas, Serkan, Horakova, Dana, Kubala Havrdova, Eva, Grand’Maison, Francois, Alroughani, Raed, Gerlach, Oliver, Amato, Maria Pia, Altintas, Ayse, Girard, Marc, Duquette, Pierre, Blanco, Yolanda, Ramo-Tello, Cristina, Laureys, Guy, Kalincik, Tomas, Khoury, Samia J., Shaygannejad, Vahid, Etemadifar, Masoud, Singhal, Bhim, Mrabet, Saloua, Foschi, Matteo, Habek, Mario, John, Nevin, Hughes, Stella, McCombe, Pamela, Ampapa, Radek, van der Walt, Anneke, Butzkueven, Helmut, de Gans, Koen, McGuigan, Chris, Oreja-Guevara, Celia, Sa, Maria Jose, Petersen, Thor, Al-Harbi, Talal, Sempere, Angel Perez, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Prevost, Julie, Gray, Orla, Castillo-Triviño, Tamara, Macdonell, Richard, Lugaresi, Alessandra, Sajedi, Seyed Aidin, and van der Mei, Ingrid

Published
2024
Full Text
View/download PDF

3. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author

Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, Vukusic, Sandra, Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, and Kalincik, Tomas

Published
2024
Full Text
View/download PDF

4. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders

Author

Lu, Angelo, Zimmermann, Hanna G, Specovius, Svenja, Motamedi, Seyedamirhosein, Chien, Claudia, Bereuter, Charlotte, Lana-Peixoto, Marco A, Fontenelle, Mariana Andrade, Ashtari, Fereshteh, Kafieh, Rahele, Dehghani, Alireza, Pourazizi, Mohsen, Pandit, Lekha, D'Cunha, Anitha, Kim, Ho Jin, Hyun, Jae-Won, Jung, Su-Kyung, Leocani, Letizia, Pisa, Marco, Radaelli, Marta, Siritho, Sasitorn, May, Eugene F, Tongco, Caryl, De Sèze, Jérôme, Senger, Thomas, Palace, Jacqueline, Roca-Fernández, Adriana, Leite, Maria Isabel, Sharma, Srilakshmi M, Stiebel-Kalish, Hadas, Asgari, Nasrin, Soelberg, Kerstin Kathrine, Martinez-Lapiscina, Elena H, Havla, Joachim, Mao-Draayer, Yang, Rimler, Zoe, Reid, Allyson, Marignier, Romain, Cobo-Calvo, Alvaro, Altintas, Ayse, Tanriverdi, Uygur, Yildirim, Rengin, Aktas, Orhan, Ringelstein, Marius, Albrecht, Philipp, Tavares, Ivan Maynart, Bichuetti, Denis Bernardi, Jacob, Anu, Huda, Saif, de Castillo, Ibis Soto, Petzold, Axel, Green, Ari J, Yeaman, Michael R, Smith, Terry J, Cook, Lawrence, Paul, Friedemann, Brandt, Alexander U, and Oertel, Frederike Cosima

Subjects
Eye Disease and Disorders of Vision, Brain Disorders, Neurosciences, Neurodegenerative, Adult, Aquaporin 4, Astrocytes, Autoantibodies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Neuromyelitis Optica, Retina, Tomography, Optical Coherence, vision, clinical neurology, ophthalmology, GJCF International Clinical Consortium for NMOSD, Medical and Health Sciences, Psychology and Cognitive Sciences, Neurology & Neurosurgery
Abstract

BackgroundPatients with anti-aquaporin-4 antibody seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorders (NMOSDs) frequently suffer from optic neuritis (ON) leading to severe retinal neuroaxonal damage. Further, the relationship of this retinal damage to a primary astrocytopathy in NMOSD is uncertain. Primary astrocytopathy has been suggested to cause ON-independent retinal damage and contribute to changes particularly in the outer plexiform layer (OPL) and outer nuclear layer (ONL), as reported in some earlier studies. However, these were limited in their sample size and contradictory as to the localisation. This study assesses outer retinal layer changes using optical coherence tomography (OCT) in a multicentre cross-sectional cohort.Method197 patients who were AQP4-IgG+ and 32 myelin-oligodendrocyte-glycoprotein antibody seropositive (MOG-IgG+) patients were enrolled in this study along with 75 healthy controls. Participants underwent neurological examination and OCT with central postprocessing conducted at a single site.ResultsNo significant thinning of OPL (25.02±2.03 µm) or ONL (61.63±7.04 µm) were observed in patients who were AQP4-IgG+ compared with patients who were MOG-IgG+ with comparable neuroaxonal damage (OPL: 25.10±2.00 µm; ONL: 64.71±7.87 µm) or healthy controls (OPL: 24.58±1.64 µm; ONL: 63.59±5.78 µm). Eyes of patients who were AQP4-IgG+ (19.84±5.09 µm, p=0.027) and MOG-IgG+ (19.82±4.78 µm, p=0.004) with a history of ON showed parafoveal OPL thinning compared with healthy controls (20.99±5.14 µm); this was not observed elsewhere.ConclusionThe results suggest that outer retinal layer loss is not a consistent component of retinal astrocytic damage in AQP4-IgG+ NMOSD. Longitudinal studies are necessary to determine if OPL and ONL are damaged in late disease due to retrograde trans-synaptic axonal degeneration and whether outer retinal dysfunction occurs despite any measurable structural correlates.

Published
2022

5. Retinal Optical Coherence Tomography in Neuromyelitis Optica.

Author

Oertel, Frederike, Specovius, Svenja, Zimmermann, Hanna, Chien, Claudia, Motamedi, Seyedamirhosein, Bereuter, Charlotte, Cook, Lawrence, Lana Peixoto, Marco, Fontanelle, Mariana, Kim, Ho, Hyun, Jae-Won, Palace, Jacqueline, Roca-Fernandez, Adriana, Leite, Maria, Sharma, Srilakshmi, Ashtari, Fereshteh, Kafieh, Rahele, Dehghani, Alireza, Pourazizi, Mohsen, Pandit, Lekha, DCunha, Anitha, Aktas, Orhan, Ringelstein, Marius, Albrecht, Philipp, May, Eugene, Tongco, Caryl, Leocani, Letizia, Pisa, Marco, Radaelli, Marta, Martinez-Lapiscina, Elena, Stiebel-Kalish, Hadas, Siritho, Sasitorn, de Seze, Jérome, Senger, Thomas, Havla, Joachim, Marignier, Romain, Cobo-Calvo, Alvaro, Bichuetti, Denis, Tavares, Ivan, Asgari, Nasrin, Soelberg, Kerstin, Altintas, Ayse, Yildirim, Rengin, Tanriverdi, Uygur, Jacob, Anu, Huda, Saif, Rimler, Zoe, Reid, Allyson, Mao-Draayer, Yang, Soto de Castillo, Ibis, Petzold, Axel, Green, Ari, Yeaman, Michael, Smith, Terry, Brandt, Alexander, and Paul, Friedemann

Subjects
Adult, Aquaporin 4, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Neuromyelitis Optica, Optic Neuritis, Retinal Neurons, Retrospective Studies, Tomography, Optical Coherence, Young Adult
Abstract

BACKGROUND AND OBJECTIVES: To determine optic nerve and retinal damage in aquaporin-4 antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorders (NMOSD) in a large international cohort after previous studies have been limited by small and heterogeneous cohorts. METHODS: The cross-sectional Collaborative Retrospective Study on retinal optical coherence tomography (OCT) in neuromyelitis optica collected retrospective data from 22 centers. Of 653 screened participants, we included 283 AQP4-IgG-seropositive patients with NMOSD and 72 healthy controls (HCs). Participants underwent OCT with central reading including quality control and intraretinal segmentation. The primary outcome was thickness of combined ganglion cell and inner plexiform (GCIP) layer; secondary outcomes were thickness of peripapillary retinal nerve fiber layer (pRNFL) and visual acuity (VA). RESULTS: Eyes with ON (NMOSD-ON, N = 260) or without ON (NMOSD-NON, N = 241) were assessed compared with HCs (N = 136). In NMOSD-ON, GCIP layer (57.4 ± 12.2 μm) was reduced compared with HC (GCIP layer: 81.4 ± 5.7 μm, p < 0.001). GCIP layer loss (-22.7 μm) after the first ON was higher than after the next (-3.5 μm) and subsequent episodes. pRNFL observations were similar. NMOSD-NON exhibited reduced GCIP layer but not pRNFL compared with HC. VA was greatly reduced in NMOSD-ON compared with HC eyes, but did not differ between NMOSD-NON and HC. DISCUSSION: Our results emphasize that attack prevention is key to avoid severe neuroaxonal damage and vision loss caused by ON in NMOSD. Therapies ameliorating attack-related damage, especially during a first attack, are an unmet clinical need. Mild signs of neuroaxonal changes without apparent vision loss in ON-unaffected eyes might be solely due to contralateral ON attacks and do not suggest clinically relevant progression but need further investigation.

Published
2021

6. Anti-vascular endothelial growth factor therapy in diabetic macular edema: real-life outcomes from a multicenter study in Turkey over 36 months

Author

Durukan, Ali Hakan, Unlu, Nurten, Onen, Mehmet, Alp, Mehmet Numan, Yeşiltaş, Yağmur Seda, Kalayci, Defne, Acar, Mehmet Akif, Sekeroglu, Mehmet Ali, Citirik, Mehmet, Altintas, Ayse Gul Kocak, Hazirolan, Dicle, Kucukevcilioglu, Murat, Ozdal, Pinar Cakar, Toklu, Yasin, Bicer, Tolga, Ugurlu, Nagihan, Budakoglu, Ozlem, Yazar, Zeliha, Ucgun, Nil Irem, Serdar, Kurtulus, Doguizi, Sibel, Erol, Yasemin Ozdamar, Atilgan, Cemile Ucgul, Yorgun, Mucella Arikan, Soba, Dilek Ozcelik, Berker, Nilufer, Baskan, Ceyda, and Yilmaz, Esra Safak

Published
2022
Full Text
View/download PDF

7. Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO).

Author

Specovius, Svenja, Zimmermann, Hanna G, Oertel, Frederike Cosima, Chien, Claudia, Bereuter, Charlotte, Cook, Lawrence J, Lana Peixoto, Marco Aurélio, Fontenelle, Mariana Andrade, Kim, Ho Jin, Hyun, Jae-Won, Jung, Su-Kyung, Palace, Jacqueline, Roca-Fernandez, Adriana, Diaz, Alejandro Rubio, Leite, Maria Isabel, Sharma, Srilakshmi M, Ashtari, Fereshte, Kafieh, Rahele, Dehghani, Alireza, Pourazizi, Mohsen, Pandit, Lekha, Dcunha, Anitha, Aktas, Orhan, Ringelstein, Marius, Albrecht, Philipp, May, Eugene, Tongco, Caryl, Leocani, Letizia, Pisa, Marco, Radaelli, Marta, Martinez-Lapiscina, Elena H, Stiebel-Kalish, Hadas, Hellmann, Mark, Lotan, Itay, Siritho, Sasitorn, de Seze, Jérôme, Senger, Thomas, Havla, Joachim, Marignier, Romain, Tilikete, Caroline, Cobo Calvo, Alvaro, Bichuetti, Denis Bernardi, Tavares, Ivan Maynart, Asgari, Nasrin, Soelberg, Kerstin, Altintas, Ayse, Yildirim, Rengin, Tanriverdi, Uygur, Jacob, Anu, Huda, Saif, Rimler, Zoe, Reid, Allyson, Mao-Draayer, Yang, de Castillo, Ibis Soto, Yeaman, Michael R, Smith, Terry J, Brandt, Alexander U, Paul, Friedemann, and GJCF International Clinical Consortium for NMOSD

Subjects
GJCF International Clinical Consortium for NMOSD, medical retina, neuro-ophthalmology, neurology, radiology & imaging, radiology &amp, imaging, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

PurposeOptical coherence tomography (OCT) captures retinal damage in neuromyelitis optica spectrum disorders (NMOSD). Previous studies investigating OCT in NMOSD have been limited by the rareness and heterogeneity of the disease. The goal of this study was to establish an image repository platform, which will facilitate neuroimaging studies in NMOSD. Here we summarise the profile of the Collaborative OCT in NMOSD repository as the initial effort in establishing this platform. This repository should prove invaluable for studies using OCT to investigate NMOSD.ParticipantsThe current cohort includes data from 539 patients with NMOSD and 114 healthy controls. These were collected at 22 participating centres from North and South America, Asia and Europe. The dataset consists of demographic details, diagnosis, antibody status, clinical disability, visual function, history of optic neuritis and other NMOSD defining attacks, and OCT source data from three different OCT devices.Findings to dateThe cohort informs similar demographic and clinical characteristics as those of previously published NMOSD cohorts. The image repository platform and centre network continue to be available for future prospective neuroimaging studies in NMOSD. For the conduct of the study, we have refined OCT image quality criteria and developed a cross-device intraretinal segmentation pipeline.Future plansWe are pursuing several scientific projects based on the repository, such as analysing retinal layer thickness measurements, in this cohort in an attempt to identify differences between distinct disease phenotypes, demographics and ethnicities. The dataset will be available for further projects to interested, qualified parties, such as those using specialised image analysis or artificial intelligence applications.

Published
2020

8. Sex effects across the lifespan in women with multiple sclerosis

Author

Krysko, Kristen M, Graves, Jennifer S, Dobson, Ruth, Altintas, Ayse, Amato, Maria Pia, Bernard, Jacqueline, Bonavita, Simona, Bove, Riley, Cavalla, Paola, Clerico, Marinella, Corona, Teresa, Doshi, Anisha, Fragoso, Yara, Jacobs, Dina, Jokubaitis, Vilija, Landi, Doriana, Llamosa, Gloria, Longbrake, Erin E, Maillart, Elisabeth, Marta, Monica, Midaglia, Luciana, Shah, Suma, Tintore, Mar, van der Walt, Anneke, Voskuhl, Rhonda, Wang, Yujie, Zabad, Rana K, Zeydan, Burcu, Houtchens, Maria, and Hellwig, Kerstin

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Neurosciences, Contraception/Reproduction, Aging, Neurodegenerative, Multiple Sclerosis, Prevention, Autoimmune Disease, Brain Disorders, 2.1 Biological and endogenous factors, Aetiology, Neurological, Reproductive health and childbirth, Good Health and Well Being, breastfeeding, multiple sclerosis, pregnancy, sex differences, sex hormones, women
Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous system disorder that is more common in women, with onset often during reproductive years. The female:male sex ratio of MS rose in several regions over the last century, suggesting a possible sex by environmental interaction increasing MS risk in women. Since many with MS are in their childbearing years, family planning, including contraceptive and disease-modifying therapy (DMT) counselling, are important aspects of MS care in women. While some DMTs are likely harmful to the developing fetus, others can be used shortly before or until pregnancy is confirmed. Overall, pregnancy decreases risk of MS relapses, whereas relapse risk may increase postpartum, although pregnancy does not appear to be harmful for long-term prognosis of MS. However, ovarian aging may contribute to disability progression in women with MS. Here, we review sex effects across the lifespan in women with MS, including the effect of sex on MS susceptibility, effects of pregnancy on MS disease activity, and management strategies around pregnancy, including risks associated with DMT use before and during pregnancy, and while breastfeeding. We also review reproductive aging and sexual dysfunction in women with MS.

Published
2020

11. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

Author

Dekeyser, Cathérine, primary, Hautekeete, Matthias, additional, Cambron, Melissa, additional, Van Pesch, Vincent, additional, Patti, Francesco, additional, Kuhle, Jens, additional, Khoury, Samia, additional, Lechner Scott, Jeanette, additional, Gerlach, Oliver, additional, Lugaresi, Alessandra, additional, Maimone, Davide, additional, Surcinelli, Andrea, additional, Grammond, Pierre, additional, Kalincik, Tomas, additional, Habek, Mario, additional, Willekens, Barbara, additional, Macdonell, Richard, additional, Lalive, Patrice, additional, Csepany, Tunde, additional, Butzkueven, Helmut, additional, Boz, Cavit, additional, Tomassini, Valentina, additional, Foschi, Matteo, additional, Sánchez-Menoyo, José Luis, additional, Altintas, Ayse, additional, Mrabet, Saloua, additional, Iuliano, Gerardo, additional, Sa, Maria Jose, additional, Alroughani, Raed, additional, Karabudak, Rana, additional, Aguera-Morales, Eduardo, additional, Gray, Orla, additional, de Gans, Koen, additional, van der Walt, Anneke, additional, McCombe, Pamela A, additional, Deri, Norma, additional, Garber, Justin, additional, Al-Asmi, Abdullah, additional, Skibina, Olga, additional, Duquette, Pierre, additional, Cartechini, Elisabetta, additional, Spitaleri, Daniele, additional, Gouider, Riadh, additional, Soysal, Aysun, additional, Van Hijfte, Liesbeth, additional, Slee, Mark, additional, Amato, Maria Pia, additional, Buzzard, Katherine, additional, and Laureys, Guy, additional

Published
2024
Full Text
View/download PDF

14. State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis

Author

Sá, María José, Soares dos Reis, Ricardo, Altintas, Ayse, Celius, Elisabeth Gulowsen, Chien, Claudia, Comi, Giancarlo, Graus, Francesc, Hillert, Jan, Hobart, Jeremy, Khan, Gulfaraz, Kissani, Najib, Langdon, Dawn, Leite, Maria Isabel, Okuda, Darin T., Palace, Jacqueline, Papais-Alvarenga, Regina María, Mendes-Pinto, Inês, and Shi, Fu-Dong

Published
2020
Full Text
View/download PDF

15. Comparative analysis of fingolimod versus teriflunomide in relapsing–remitting multiple sclerosis

Author

Boz, Cavit, Terzi, Murat, Özer, Bilge, Turkoglu, Recai, Karabudak, Rana, Efendi, Hüsnü, Soysal, Aysun, Sevim, Serhan, Altintas, Ayse, Kurne, Asli, Akçalı, Aylin, Akman, Gülsen, Yüceyar, Nur, Balcı, Belgin Petek, Ekmekci, Özgul, Karahan, Serap Zengin, Demirkıran, Meltem, Altunrende, Burcu, Turan, Ömer Faruk, Gökçen GözübatıkÇelik, Kale, Nilüfer, Köseoğlu, Mesrure, and Ozakbas, Serkan

Published
2019
Full Text
View/download PDF

17. Nonisolated forms of rational triple point singularities of surfaces and their resolutions

Author

Altintas, Ayse, Cevik, Gulen, and Tosun, Meral

Subjects
Mathematics - Algebraic Geometry, 58K20
Abstract

The work is a detailed study of rational singularities of multiplicity 3 (RTP-singularities, for short). We give a list of nonisolated hypersurface singularities of which normalisations are the RTP-singularities, and construct their minimal resolution graphs by means of a subdivision of Newton polygons of those -- a method introduced by M. Oka for isolated complete intersection singularities. We show that nonisolated forms of RTP-singularities and their normalisations are both Newton non-degenerate., Comment: 22 pages, 43 figures, v3

Published
2013

18. Examples of finitely determined map-germs of corank 2 from $n$-space to $(n+1)$-space

Author

Altintas, Ayse

Subjects
Mathematics - Algebraic Geometry, 58K40, 32S30
Abstract

We produce new examples supporting the Mond conjecture which can be stated as follows. The number of parameters needed for a miniversal unfolding of a finitely determined map-germ from $n$-space to $(n+1)$-space is less than (or equal to if the map-germ is weighted homogeneous) the rank of the $n$th homology group of the image of a stable perturbation of the map-germ. We give examples of finitely determined map-germs of corank 2 from 3-space to 4-space satisfying the conjecture. We introduce a new type of augmentations to generate series of finitely determined map-germs in dimensions $(n,n+1)$ from a given one in dimensions $(n-1,n)$. We present more examples in dimensions $(4,5)$ and $(5,6)$ based on our examples, and verify the conjecture for them., Comment: v3: final version, to appear in International Journal of Mathematics. -- v2: 14 pages, shortened and revised: section on map-germs from 3-space to 4-space removed, the examples kept; remark 4.11 corrected, now it is remark 4.4; remark 4.12 revised; replaced the term 'reduction' with 'augmentation'

Published
2012

19. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author

Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, and Vukusic, Sandra

Abstract

High-efficacy disease-modifying therapies have been proven to slow disability accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on disability worsening in paediatric-onset multiple sclerosis, particularly during the early phases, is not well understood. We evaluated how high-efficacy therapies influence transitions across five disability states, ranging from minimal disability to gait impairment and secondary progressive multiple sclerosis, in people with paediatric-onset multiple sclerosis.

Published
2024
Full Text
View/download PDF

20. Free resolutions for multiple point spaces

Author

Altintas, Ayse and Mond, David

Subjects
Mathematics - Algebraic Geometry, 58K20
Abstract

Let f be a map-germ of corank 1 from complex n-space to complex (n+1)-space, and, for k less than or equal to the multiplicity of f, let $D^k(f)$ be its k'th multiple-point scheme -- the closure of the set of ordered k-tuples of pairwise distinct points sharing the same image. There are natural projections from $D^{k+1}(f)$ to $D^k(f)$, determined by forgetting one member of the (k+1)-tuple. We prove that the matrix of a presentation of $\OO_{D^{k+1}(f)}$ over $\OO_{D^k(f)}$ appears as a certain submatrix of the matrix of a suitable presentation of $\OO_{\CC^n}$ over $\OO_{\CC^{n+1}}$. This does not happen for germs of corank greater than 1., Comment: 15 pages

Published
2011
Full Text
View/download PDF

21. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.

Author

Spelman, Tim, Simoneau, Gabrielle, Hyde, Robert, Kuhelj, Robert, Alroughani, Raed, Ozakbas, Serkan, Karabudak, Rana, Yamout, Bassem I., Khoury, Samia J., Terzi, Murat, Boz, Cavit, Horakova, Dana, Havrdova, Eva Kubala, Weinstock-Guttman, Bianca, Patti, Francesco, Altintas, Ayse, Mrabet, Saloua, Gouider, Riadh, Inshasi, Jihad, and Shaygannejad, Vahid

Published
2024
Full Text
View/download PDF

23. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

Author

Bovis, Francesca, Kalincik, Tomas, Lublin, Fred, Cutter, Gary, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Terzi, Murat, Grammond, Pierre, Bergamaschi, Roberto, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Iuliano, Gerardo, Boz, Cavit, Hupperts, Raymond, GrandʼMaison, Francois, Oreja-Guevara, Celia, van Pesch, Vincent, Cartechini, Elisabetta, Petersen, Thor, Altintas, Ayse, Soysal, Aysun, Ramo-Tello, Cristina, McCombe, Pamela, Turkoglu, Recai, Butzkueven, Helmut, Wolinsky, Jerry S., Solaro, Claudio, and Sormani, Maria Pia

Published
2021
Full Text
View/download PDF

24. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, Sifat, primary, Roos, Izanne, additional, Simpson-Yap, Steve, additional, Malpas, Charles, additional, Sánchez, Marina M, additional, Ozakbas, Serkan, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Patti, Francesco, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Boz, Cavit, additional, Zakaria, Magd, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Weinstock-Guttman, Bianca, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Amato, Maria Pia, additional, Karabudak, Rana, additional, Grand’Maison, Francois, additional, Khoury, Samia J, additional, Grammond, Pierre, additional, Lechner-Scott, Jeannette, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Turkoglu, Recai, additional, Altintas, Ayse, additional, Maimone, Davide, additional, Kermode, Allan, additional, Shalaby, Nevin, additional, Pesch, Vincent V, additional, Butler, Ernest, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Mrabet, Saloua, additional, Gerlach, Oliver, additional, Soysal, Aysun, additional, Barnett, Michael, additional, Kuhle, Jens, additional, Hughes, Stella, additional, Sa, Maria J, additional, Hodgkinson, Suzanne, additional, Oreja-Guevara, Celia, additional, Ampapa, Radek, additional, Petersen, Thor, additional, Ramo-Tello, Cristina, additional, Spitaleri, Daniele, additional, McCombe, Pamela, additional, Taylor, Bruce, additional, Prevost, Julie, additional, Foschi, Matteo, additional, Slee, Mark, additional, McGuigan, Chris, additional, Laureys, Guy, additional, Hijfte, Liesbeth V, additional, de Gans, Koen, additional, Solaro, Claudio, additional, Oh, Jiwon, additional, Macdonell, Richard, additional, Aguera-Morales, Eduardo, additional, Singhal, Bhim, additional, Gray, Orla, additional, Garber, Justin, additional, Wijmeersch, Bart V, additional, Simu, Mihaela, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose L, additional, Khurana, Dheeraj, additional, Al-Asmi, Abdullah, additional, Al-Harbi, Talal, additional, Deri, Norma, additional, Fragoso, Yara, additional, Lalive, Patrice H, additional, Sinnige, L G F, additional, Shaw, Cameron, additional, Shuey, Neil, additional, Csepany, Tunde, additional, Sempere, Angel P, additional, Moore, Fraser, additional, Decoo, Danny, additional, Willekens, Barbara, additional, Gobbi, Claudio, additional, Massey, Jennifer, additional, Hardy, Todd, additional, Parratt, John, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

26. Disability accrual in primary and secondary progressive multiple sclerosis

Author

Harding-Forrester, Sam, primary, Roos, Izanne, additional, Nguyen, Ai-Lan, additional, Malpas, Charles B, additional, Diouf, Ibrahima, additional, Moradi, Nahid, additional, Sharmin, Sifat, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Patti, Francesco, additional, Horakova, Dana, additional, Kubala Havrdova, Eva, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Grand'Maison, Francois, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Ozakbas,, Serkan, additional, Amato, Maria Pia, additional, Gerlach, Oliver, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Lechner-Scott, Jeannette, additional, Alroughani, Raed, additional, Boz, Cavit, additional, Van Pesch, Vincent, additional, Cartechini, Elisabetta, additional, Terzi, Murat, additional, Maimone, Davide, additional, Ramo-Tello, Cristina, additional, Yamout, Bassem, additional, Khoury, Samia Joseph, additional, La Spitaleri, Daniele, additional, Sa, Maria Jose, additional, Blanco, Yolanda, additional, Granella, Franco, additional, Slee, Mark, additional, Butler, Ernest, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Ampapa, Radek, additional, Sánchez-Menoyo, José Luis, additional, Prevost, Julie, additional, Castillo-Trivino, Tamara, additional, McCombe, Pamela A, additional, Macdonell, Richard, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Oh, Jiwon, additional, Altintas, Ayse, additional, de Gans, Koen, additional, Turkoglu, Recai, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Vucic, Steve, additional, Barnett, Michael, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Iuliano, Gerardo, additional, Kappos, Ludwig, additional, Kuhle, Jens, additional, Shaygannejad, Vahid, additional, Soysal, Aysun, additional, Weinstock-Guttman, Bianca, additional, Van Wijmeersch, Bart, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

27. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author

Daruwalla, Cyrus, primary, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Havrdova, Eva Kubala, additional, Horakova, Dana, additional, Alroughani, Raed, additional, Boz, Cavit, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Duquette, Pierre, additional, Yamout, Bassem, additional, Khoury, Samia J, additional, Sajedi, Seyed Aidin, additional, Turkoglu, Recai, additional, Altintas, Ayse, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Grammond, Pierre, additional, Karabudak, Rana, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Soysal, Aysun, additional, John, Nevin, additional, Prevost, Julie, additional, Spitaleri, Daniele, additional, Ramo-Tello, Cristina, additional, Gerlach, Oliver, additional, Iuliano, Gerardo, additional, Foschi, Matteo, additional, Ampapa, Radek, additional, van Pesch, Vincent, additional, Barnett, Michael, additional, Shalaby, Nevin, additional, D’hooghe, Marie, additional, Kuhle, Jens, additional, Sa, Maria Jose, additional, Fabis-Pedrini, Marzena, additional, Kermode, Allan, additional, Mrabet, Saloua, additional, Gouider, Riadh, additional, Hodgkinson, Suzanne, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Macdonell, Richard, additional, Oreja-Guevara, Celia, additional, Cristiano, Edgardo, additional, McCombe, Pamela, additional, Sanchez-Menoyo, Jose Luis, additional, Singhal, Bhim, additional, Blanco, Yolanda, additional, Hughes, Stella, additional, Garber, Justin, additional, Solaro, Claudio, additional, McGuigan, Chris, additional, Taylor, Bruce, additional, de Gans, Koen, additional, Habek, Mario, additional, Al-Asmi, Abdullah, additional, Mihaela, Simu, additional, Castillo Triviño, Tamara, additional, Al-Harbi, Talal, additional, Rojas, Juan Ignacio, additional, Gray, Orla, additional, Khurana, Dheeraj, additional, Van Wijmeersch, Bart, additional, Grigoriadis, Nikolaos, additional, Inshasi, Jihad, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Fragoso, Yara, additional, Moore, Fraser, additional, Shaw, Cameron, additional, Baghbanian, Seyed Mohammad, additional, Shuey, Neil, additional, Willekens, Barbara, additional, Hardy, Todd A, additional, Decoo, Danny, additional, sempere, Angel Perez, additional, Field, Deborah, additional, Wynford-Thomas, Ray, additional, Cunniffe, Nick G, additional, Roos, Izanne, additional, Malpas, Charles B, additional, Coles, Alasdair J, additional, Kalincik, Tomas, additional, and Brown, J William L, additional

Published
2023
Full Text
View/download PDF

28. Comparative effectiveness in multiple sclerosis: A methodological comparison

Author

Roos, Izanne, primary, Diouf, Ibrahima, additional, Sharmin, Sifat, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamou, Bassem, additional, Altintas, Ayse, additional, Gerlach, Oliver, additional, van Pesch, Vincent, additional, Blanco, Yolanda, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, McGuigan, Chris, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria José, additional, Solaro, Claudio, additional, Ramo-Tello, Cristina, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Granella, Franco, additional, de Gans, Koen, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Prevost, Julie, additional, Sanchez-Menoyo, Jose Luis, additional, Laureys, Guy, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Gray, Orla, additional, Aguera-Morales, Eduardo, additional, Al-Asmi, Abdullah, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Sempere, Angel Perez, additional, Trevino-Frenk, Irene, additional, Schepel, Jan, additional, Moore, Fraser, additional, Malpas, Charles, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

29. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Author

Diouf, Ibrahima, primary, Malpas, Charles B., additional, Sharmin, Sifat, additional, Roos, Izanne, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand'Maison, Francois, additional, Hamdy, Sherif, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamout, Bassem, additional, Altintas, Ayse, additional, Gerlach, Oliver, additional, van Pesch, Vincent, additional, Blanco, Yolanda, additional, Maimone, Davide, additional, Lechner‐Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Iuliano, Gerardo, additional, McGuigan, Chris, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria José, additional, Solaro, Claudio, additional, Kappos, Ludwig, additional, Ramo‐Tello, Cristina, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Slee, Mark, additional, Butler, Ernest, additional, Granella, Franco, additional, de Gans, Koen, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Prevost, Julie, additional, Sinnige, L. G. F., additional, Sanchez‐Menoyo, Jose Luis, additional, Vucic, Steve, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Khurana, Dheeraj, additional, Macdonell, Richard, additional, Gouider, Riadh, additional, Castillo‐Triviño, Tamara, additional, Gray, Orla, additional, Aguera‐Morales, Eduardo, additional, Al‐Asmi, Abdullah, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al‐Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Perez Sempere, Angel, additional, Trevino‐Frenk, Irene, additional, Schepel, Jan, additional, Moore, Fraser, additional, and Kalincik, Tomas, additional

Published
2023
Full Text
View/download PDF

31. Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch

Author

Kucukevcilioglu, Murat, primary, Yeşiltaş, Yağmur Seda, additional, Durukan, Ali Hakan, additional, Unlu, Nurten, additional, Onen, Mehmet, additional, Alp, Mehmet Numan, additional, Kalayci, Defne, additional, Acar, Mehmet Akif, additional, Sekeroglu, Mehmet Ali, additional, Citirik, Mehmet, additional, Altintas, Ayse Gul Kocak, additional, Hazirolan, Dicle, additional, Ozdal, Pinar Cakar, additional, Toklu, Yasin, additional, Bicer, Tolga, additional, Ugurlu, Nagihan, additional, Budakoglu, Ozlem, additional, Yazar, Zeliha, additional, Zeki, Nil Irem Ucgun, additional, Serdar, Kurtulus, additional, Doguizi, Sibel, additional, Erol, Yasemin Ozdamar, additional, Atilgan, Cemile Ucgul, additional, Yorgun, Mucella Arikan, additional, Soba, Dilek Ozcelik, additional, Berker, Nilufer, additional, and Baskan, Ceyda, additional

Published
2023
Full Text
View/download PDF

35. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Author

Spelman, Tim, primary, Ozakbas, Serkan, additional, Alroughani, Raed, additional, Terzi, Murat, additional, Hodgkinson, Suzanne, additional, Laureys, Guy, additional, Kalincik, Tomas, additional, Van Der Walt, Anneke, additional, Yamout, Bassem, additional, Lechner-Scott, Jeannette, additional, Soysal, Aysun, additional, Kuhle, Jens, additional, Sanchez-Menoyo, Jose Luis, additional, Blanco Morgado, Yolanda, additional, Spitaleri, Daniele LA, additional, van Pesch, Vincent, additional, Horakova, Dana, additional, Ampapa, Radek, additional, Patti, Francesco, additional, Macdonell, Richard, additional, Al-Asmi, Abdullah, additional, Gerlach, Oliver, additional, Oh, Jiwon, additional, Altintas, Ayse, additional, Tundia, Namita, additional, Wong, Schiffon L, additional, and Butzkueven, Helmut, additional

Published
2022
Full Text
View/download PDF

36. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis

Author

Kalincik, Tomas, Sharmin, Sifat, Roos, Izanne, Freedman, Mark S., Atkins, Harold, Burman, Joachim, Massey, Jennifer, Sutton, Ian, Withers, Barbara, Macdonell, Richard, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trněný, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, McCombe, Pamela, Skibina, Olga, Lechner-Scott, Jeannette, Willekens, Barbara, Cartechini, Elisabetta, Ozakbas, Serkan, Alroughani, Raed, Kuhle, Jens, Patti, Francesco, Duquette, Pierre, Lugaresi, Alessandra, Khoury, Samia J., Slee, Mark, Turkoglu, Recai, Hodgkinson, Suzanne, John, Nevin, Maimone, Davide, Sa, Maria Jose, van Pesch, Vincent, Gerlach, Oliver, Laureys, Guy, Van Hijfte, Liesbeth, Karabudak, Rana, Spitaleri, Daniele, Csepany, Tunde, Gouider, Riadh, Castillo-Triviño, Tamara, Taylor, Bruce, Sharrack, Basil, Snowden, John A., Horakova, Dana, Buzzard, Katherine, Terzi, Murat, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Barnett, Michael, Stewart, Grace, Onofrj, Marco, Izquierdo, Guillermo, Eichau, Sara, Grand'Maison, Francois, Prevost, Julie, Van Wijmeersch, Bart, Amato, Maria Pia, Shaygannejad, Vahid, Boz, Cavit, Bolaños, Ricardo Fernandez, Soysal, Aysun, Ramo-Tello, Cristina, Solaro, Claudio, Gobbi, Claudio, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Deri, Norma, Saladino, Maria Laura, Cristiano, Edgardo, Rojas, Juan Ignacio, Vrech, Carlos, Shaw, Cameron, Shuey, Neil, Boggild, Mike, Tan, Ik Lin, Hardy, Todd, Decoo, Danny, Moore, Fraser, Oh, Jiwon, Lalive, Patrice, Ampapa, Radek, Petersen, Thor, Oreja-Guevara, Celia, Perez Sempere, Angel, Dominguez, Jose Andres, Besora, Sarah, Hughes, Stella, Gray, Orla, Grigoriadis, Nikolaos, Piroska, Imre, Rozsa, Csilla, Kasa, Krisztian, Simo, Magdolna, Kovacs, Krisztina, Sas, Attila, Dobos, Eniko, Rajda, Cecilia, McGuigan, Chris, Mason, Deborah, Schepel, Jan, Alkhaboori, Jabir, Rio, Maria Edite, Mihaela, Simu, Al-Harbi, Talal, Altintas, Ayse, Kister, Ilya, Marriott, Mark, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Diamanti, Matteo, Chisari, Clara, Toscano, Simona, Salvatore, Lo Fermo, Larochelle, Catherine, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Hupperts, Raymond, Olascoaga, Javier, Saiz, Albert, Zivadinov, Robert, Benedict, Ralph, Verheul, Freek, Fabis-Pedrini, Marzena, Mrabet, Saloua, Garber, Justin, Sanchez-Menoyo, Jose Luis, Aguera-Morales, Eduardo, Blanco, Yolanda, Al-Asmi, Abdullah, Weinstock-Guttman, Bianca, Fragoso, Yara, de Gans, Koen, and Kermode, Allan

Subjects
Human medicine
Abstract

you are agreeing to our Cookie Policy | Continue JAMA Network HomeJAMA Neurology This Issue Views 2,357 Citations 0 60 Full Text Share Comment Original Investigation May 15, 2023 Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis Tomas Kalincik, MD, PhD1,2; Sifat Sharmin, PhD1,2; Izanne Roos, MBChB, PhD1,2; Mark S. Freedman, MD3; Harold Atkins, MD4; Joachim Burman, MD, PhD5; Jennifer Massey, MBBS, PhD6,7; Ian Sutton, MBBS, PhD6,8; Barbara Withers, MD, PhD7,9; Richard Macdonell, MD, PhD10,11; Andrew Grigg, MD, PhD11,12; Øivind Torkildsen, MD, PhD13; Lars Bo, MD, PhD13; Anne Kristine Lehmann, MD, PhD14; Eva Kubala Havrdova, MD, PhD15; Eva Krasulova, MD, PhD15; Marek Trněný, MD, PhD16; Tomas Kozak, MD, PhD17; Anneke van der Walt, MBBS, PhD18,19; Helmut Butzkueven, MBBS, PhD18,19; Pamela McCombe, MBBS20,21; Olga Skibina, MBBS18,22,23; Jeannette Lechner-Scott, MD, PhD24,25; Barbara Willekens, MD, PhD26,27; Elisabetta Cartechini, MD28; Serkan Ozakbas, MD29; Raed Alroughani, MD30; Jens Kuhle, MD, PhD31; Francesco Patti, MD32,33; Pierre Duquette, MD34; Alessandra Lugaresi, MD, PhD35,36; Samia J. Khoury, MD, PhD37; Mark Slee, MD, PhD38; Recai Turkoglu, MD39; Suzanne Hodgkinson, MD40; Nevin John, MD, PhD41,42; Davide Maimone, MD43; Maria Jose Sa, MD44; Vincent van Pesch, MD, PhD45,46; Oliver Gerlach, MD, PhD47,48; Guy Laureys, MD49; Liesbeth Van Hijfte, MD49; Rana Karabudak, MD50; Daniele Spitaleri, MD51; Tunde Csepany, MD, PhD52; Riadh Gouider, MD53,54; Tamara Castillo-Triviño, MD55; Bruce Taylor, MD, PhD56,57; Basil Sharrack, MD, PhD58; John A. Snowden, MD, PhD59; and the MSBase Study Group Collaborators; and the MSBase Study Group Authors Author Affiliations JAMA Neurol. 2023;80(7):702-713. doi:10.1001/jamaneurol.2023.1184 editorial comment iconEditorial Comment Key Points Question What is the comparative effectiveness of autologous hematopoietic stem cell transplant (AHSCT) vs individual most potent disease-modifying therapies for relapsing-remitting multiple sclerosis (MS), such as natalizumab or ocrelizumab? Findings In this observational comparative effectiveness study of 4915 individuals using a composite cohort from specialized MS centers and the MSBase international registry, the effectiveness of AHSCT was compared with 1 medium-efficacy and 2 high-efficacy disease-modifying therapies (fingolimod, natalizumab, and ocrelizumab) in patients with relapsing-remitting MS, high frequency of relapses, and moderate disability. Over 5 years, AHSCT was associated with substantially lower relapse rate than fingolimod and marginally lower relapse rate than natalizumab and was also associated with a higher rate of recovery from disability compared with fingolimod and natalizumab, but no evidence of difference in clinical outcomes between AHSCT and ocrelizumab was found at 3-year follow-up. Meaning The results indicate that in relapsing-remitting MS, the clinical effectiveness of AHSCT is considerably superior to fingolimod and marginally superior to natalizumab. Abstract Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. Design, Setting, and Participants This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. Exposure AHSCT vs fingolimod, natalizumab, or ocrelizumab. Main outcomes Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. Results Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; the matched groups were closely aligned. The proportion of women ranged from 65% to 70%, and the mean (SD) age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from 0.77 (0.94) to 0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated with marginally lower ARR (mean [SD], 0.08 [0.31] vs 0.10 [0.34]), similar risk of disability worsening (HR, 1.06; 95% CI, 0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%]) were associated with similar ARR (mean [SD], 0.09 [0.34] vs 0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). Conclusion In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.

Published
2023

37. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

Author

Spelman, Tim, Ozakbas, Serkan, Alroughani, Raed, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele LA, Pesch, Vincent van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Al-Asmi, Abdullah, Gerlach, Oliver, Oh, Jiwon, Altintas, Ayse, Tundia, Namita, Wong, Schiffon L, Butzkueven, Helmut, MSBase Study Group, [missing], and UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire

Subjects
teriflunomide (Aubagio®), relapses, cladribine tablets, fingolimod (Gilenya®), Neurology (clinical), lay summary, dimethyl fumarate (Tecfidera®), multiple sclerosis, treatment options
Abstract

What is this summary about? Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. What were the results? Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. What do the results mean? The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.

Published
2023

38. Disability accrual in primary and secondary progressive multiple sclerosis

Author

Harding-Forrester, Sam, Roos, Izanne, Nguyen, Ai-Lan, Malpas, Charles B, Diouf, Ibrahima, Moradi, Nahid, Sharmin, Sifat, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Horakova, Dana, Kubala Havrdova, Eva, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'Maison, Francois, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ozakbas, Serkan, Amato, Maria Pia, Gerlach, Oliver, Sola, Patrizia, Ferraro, Diana, Buzzard, Katherine, Skibina, Olga, Lechner-Scott, Jeannette, Alroughani, Raed, Boz, Cavit, Van Pesch, Vincent, Cartechini, Elisabetta, Terzi, Murat, Maimone, Davide, Ramo-Tello, Cristina, Yamout, Bassem, Khoury, Samia Joseph, La Spitaleri, Daniele, Sa, Maria Jose, Blanco, Yolanda, Granella, Franco, Slee, Mark, Butler, Ernest, Sidhom, Youssef, Gouider, Riadh, Bergamaschi, Roberto, Karabudak, Rana, Ampapa, Radek, Sánchez-Menoyo, José Luis, Prevost, Julie, Castillo-Trivino, Tamara, McCombe, Pamela A, Macdonell, Richard, Laureys, Guy, Van Hijfte, Liesbeth, Oh, Jiwon, Altintas, Ayse, de Gans, Koen, Turkoglu, Recai, van der Walt, Anneke, Butzkueven, Helmut, Vucic, Steve, Barnett, Michael, Cristiano, Edgardo, Hodgkinson, Suzanne, Iuliano, Gerardo, Kappos, Ludwig, Kuhle, Jens, Shaygannejad, Vahid, Soysal, Aysun, Weinstock-Guttman, Bianca, Van Wijmeersch, Bart, Kalincik, Tomas, MSBase investigators, and UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire

Subjects
Psychiatry and Mental health, Surgery, Neurology (clinical), multiple sclerosis
Abstract

BackgroundSome studies comparing primary and secondary progressive multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive phase and similar rates of subsequent disability accrual. Others report later onset and/or faster accrual in SPMS. Comparisons have been complicated by regional cohort effects, phenotypic differences in sex ratio and management and variable diagnostic criteria for SPMS.MethodsWe compared disability accrual in PPMS and operationally diagnosed SPMS in the international, clinic-based MSBase cohort. Inclusion required PPMS or SPMS with onset at age ≥18 years since 1995. We estimated Andersen-Gill hazard ratios for disability accrual on the Expanded Disability Status Scale (EDSS), adjusted for sex, age, baseline disability, EDSS score frequency and drug therapies, with centre and patient as random effects. We also estimated ages at onset of the progressive phase (Kaplan-Meier) and at EDSS milestones (Turnbull). Analyses were replicated with physician-diagnosed SPMS.ResultsIncluded patients comprised 1872 with PPMS (47% men; 50% with activity) and 2575 with SPMS (32% men; 40% with activity). Relative to PPMS, SPMS had older age at onset of the progressive phase (median 46.7 years (95% CI 46.2–47.3) vs 43.9 (43.3–44.4); pConclusionsWe demonstrate later onset of the progressive phase and slower disability accrual in SPMS versus PPMS. This may balance greater baseline disability in SPMS, yielding convergent disability trajectories across phenotypes. The different rates of disability accrual should be considered before amalgamating PPMS and SPMS in clinical trials.

Published
2023

39. sj-docx-1-msj-10.1177_13524585231151951 – Supplemental material for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author

Daruwalla, Cyrus, Shaygannejad, Vahid, Ozakbas, Serkan, Havrdova, Eva Kubala, Horakova, Dana, Alroughani, Raed, Boz, Cavit, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J, Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Buzzard, Katherine, Grammond, Pierre, Karabudak, Rana, van der Walt, Anneke, Butzkueven, Helmut, Maimone, Davide, Lechner-Scott, Jeannette, Soysal, Aysun, John, Nevin, Prevost, Julie, Spitaleri, Daniele, Ramo-Tello, Cristina, Gerlach, Oliver, Iuliano, Gerardo, Foschi, Matteo, Ampapa, Radek, van Pesch, Vincent, Barnett, Michael, Shalaby, Nevin, D’hooghe, Marie, Kuhle, Jens, Sa, Maria Jose, Fabis-Pedrini, Marzena, Kermode, Allan, Mrabet, Saloua, Gouider, Riadh, Hodgkinson, Suzanne, Laureys, Guy, Van Hijfte, Liesbeth, Macdonell, Richard, Oreja-Guevara, Celia, Cristiano, Edgardo, McCombe, Pamela, Sanchez-Menoyo, Jose Luis, Singhal, Bhim, Blanco, Yolanda, Hughes, Stella, Garber, Justin, Solaro, Claudio, McGuigan, Chris, Taylor, Bruce, de Gans, Koen, Habek, Mario, Al-Asmi, Abdullah, Mihaela, Simu, Castillo Triviño, Tamara, Al-Harbi, Talal, Rojas, Juan Ignacio, Gray, Orla, Khurana, Dheeraj, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Inshasi, Jihad, Oh, Jiwon, Aguera-Morales, Eduardo, Fragoso, Yara, Moore, Fraser, Shaw, Cameron, Baghbanian, Seyed Mohammad, Shuey, Neil, Willekens, Barbara, Hardy, Todd A, Decoo, Danny, sempere, Angel Perez, Field, Deborah, Wynford-Thomas, Ray, Cunniffe, Nick G, Roos, Izanne, Malpas, Charles B, Coles, Alasdair J, Kalincik, Tomas, and Brown, J William L

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585231151951 for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis by Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D’hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Triviño, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A Hardy, Danny Decoo, Angel Perez sempere, Deborah Field, Ray Wynford-Thomas, Nick G Cunniffe, Izanne Roos, Charles B Malpas, Alasdair J Coles, Tomas Kalincik and J William L Brown in Multiple Sclerosis Journal

Published
2023
Full Text
View/download PDF

40. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Sánchez, Marina M, Ozakbas, Serkan, Horakova, Dana, Havrdova, Eva K, Patti, Francesco, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Boz, Cavit, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Weinstock-Guttman, Bianca, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Amato, Maria Pia, Karabudak, Rana, Grand'Maison, Francois, Khoury, Samia J, Grammond, Pierre, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Turkoglu, Recai, Altintas, Ayse, Maimone, Davide, Kermode, Allan, Shalaby, Nevin, Pesch, Vincent V, Butler, Ernest, Sidhom, Youssef, Gouider, Riadh, Mrabet, Saloua, Gerlach, Oliver, Soysal, Aysun, Barnett, Michael, Kuhle, Jens, Hughes, Stella, Maria J, Sa, Hodgkinson, Suzanne, Oreja-Guevara, Celia, Ampapa, Radek, Petersen, Thor, Ramo-Tello, Cristina, Spitaleri, Daniele, Mccombe, Pamela, Taylor, Bruce, Prevost, Julie, Foschi, Matteo, Slee, Mark, Mcguigan, Chris, Laureys, Guy, Hijfte, Liesbeth V, de Gans, Koen, Solaro, Claudio, Jiwon, Oh, Macdonell, Richard, Aguera-Morales, Eduardo, Singhal, Bhim, Gray, Orla, Garber, Justin, Wijmeersch, Bart V, Simu, Mihaela, Triviño, Tamara C, Sanchez-Menoyo, Jose L, Khurana, Dheeraj, Al-Asmi, Abdullah, Al-Harbi, Talal, Deri, Norma, Fragoso, Yara, Lalive, Patrice H, Sinnige, L G F, Shaw, Cameron, Shuey, Neil, Csepany, Tunde, Sempere, Angel P, Moore, Fraser, Decoo, Danny, Willekens, Barbara, Gobbi, Claudio, Massey, Jennifer, Hardy, Todd, Parratt, John, and Kalincik, Tomas

Subjects
secondary progressive multiple sclerosis, health expenditure, disease-modifying therapy, geography, latitude
Published
2023

42. Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort study

Author

Spelman, Tim, primary, Simoneau, Gabrielle, additional, Hyde, Robert, additional, Kuhelj, Robert, additional, Alroughani, Raed, additional, Ozakbas, Serkan, additional, Karabudak, Rana, additional, Yamout, Bassem, additional, Khoury, Samia J., additional, Terzi, Murat, additional, Boz, Cavit, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Weinstock-Guttman, Bianca, additional, Patti, Francesco, additional, Altintas, Ayse, additional, Mrabet, Saloua, additional, Inshasi, Jihad, additional, and Butzkueven, Helmut, additional

Published
2022
Full Text
View/download PDF

43. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry

Author

Sharmin, Sifat, primary, Malpas, Charles B, additional, Roos, Izanne, additional, Diouf, Ibrahima, additional, Alroughani, Raed, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Patti, Francesco, additional, Terzi, Murat, additional, Boz, Cavit, additional, Yamout, Bassem, additional, Khoury, Samia J, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Altintas, Ayse, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Sá, Maria José, additional, La Spitaleri, Daniele, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Mrabet, Saloua, additional, Soysal, Aysun, additional, Turkoglu, Recai, additional, Amato, Maria Pia, additional, Fragoso, Yara D, additional, and Kalincik, Tomas, additional

Published
2022
Full Text
View/download PDF

45. Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study

Author

De Brouwer, Edward, primary, Becker, Thijs, additional, Werthen-Brabants, Lorin, additional, Dewulf, Pieter, additional, Iliadis, Dimitrios, additional, Dekeyser, Cathérine, additional, Laureys, Guy, additional, Van Wijmeersch, Bart, additional, Popescu, Veronica, additional, Dhaene, Tom, additional, Deschrijver, Dirk, additional, Waegeman, Willem, additional, De Baets, Bernard, additional, Stock, Michiel, additional, Horakova, Dana, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Kalincik, Tomas, additional, Alroughani, Raed, additional, Grand’Maison, Francois, additional, Skibina, Olga, additional, Terzi, Murat, additional, Lechner-Scott, Jeannette, additional, Gerlach, Oliver, additional, Khoury, Samia J., additional, Cartechini, Elisabetta, additional, Van Pesch, Vincent, additional, Sa, Maria Jose, additional, Weinstock-Guttman, Bianca, additional, Blanco, Yolanda, additional, Ampapa, Radek, additional, Spitaleri, Daniele, additional, Solaro, Claudio, additional, Maimone, Davide, additional, Soysal, Aysun, additional, Iuliano, Gerardo, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose Luis, additional, van der Walt, Anneke, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Altintas, Ayse, additional, Al-Asmi, Abdullah, additional, de Gans, Koen, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Hodgkinson, Suzanne, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Taylor, Bruce, additional, Gray, Orla, additional, Lalive, Patrice, additional, Rozsa, Csilla, additional, McGuigan, Chris, additional, Kermode, Allan, additional, Perez sempere, Angel, additional, Mihaela, Simu, additional, Simo, Magdolna, additional, Hardy, Todd, additional, Decoo, Danny, additional, Hughes, Stella, additional, Grigoriadis, Nikolaos, additional, Sas, Attila, additional, Vella, Norbert, additional, Moreau, Yves, additional, and Peeters, Liesbet, additional

Published
2022
Full Text
View/download PDF

46. Problem Session

Author

Altintaş, Ayşe, Sarioğlu, Celal Cem, Bass, H., editor, Oesterlé, J., editor, Weinstein, A., editor, El Zein, Fouad, editor, Suciu, Alexandru I., editor, Tosun, Meral, editor, Uludağ, A. Muhammed, editor, and Yuzvinsky, Sergey, editor

Published
2010
Full Text
View/download PDF

49. Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi -National Registry

Author

Patti, Francesco, Sharmin, Sifat, Malpas, Charles, Roos, Izanne, Diouf, Ibrahima, Alroughani, Raed, ÖZAKBAŞ, SERKAN, Izquierdo, Guillermo, Eichau, Sara, Horakova, Dana, Havrdova, Eva Kubala, TERZİ, MURAT, BOZ, CAVİT, Yamout, Bassem, Khoury, Samia J., Onofrj, Marco, Lugaresi, Alessandra, Altintas, Ayse, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Kalincik, Tomas, Fragoso, Yara, Amato, Maria Pia, Turkoglu, Recai, Soysal, Aysun, Gouider, Riadh, Sidhom, Youssef, Spitaleri, Daniele, and Sa, Maria Jose

Published
2022

50. Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)

Author

Sharmin, Sifat, primary, Malpas, Charles, additional, Roos, Izanne, additional, Diouf, Ibrahima, additional, Alroughani, Raed, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Terzi, Murat, additional, Boz, Cavit, additional, Yamout, Bassem, additional, Khoury, Samia J., additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Altintas, Ayse, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Sa, Maria Jose, additional, Spitaleri, Daniele, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Soysal, Aysun, additional, Turkoglu, Recai, additional, Amato, Maria Pia, additional, Fragoso, Yara, additional, and Kalincik, Tomas, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results